Cite
HARVARD Citation
Alten, R. et al. (2019). Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. RMD open. 5 (1), p. . [Online].